Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999)

Clinical Infectious Diseases

Volumn 32, Issue 10 SUPPL. 2, 2001, Pages

  Gales, A C ^a   Jones, R N ^a   Forward, K R ^a   Linares J ^a   Sader, H S ^a   Verhoef, J ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; COTRIMOXAZOLE; GATIFLOXACIN; IMIPENEM; TIMENTIN; TROVAFLOXACIN;

ACINETOBACTER; ADOLESCENT; ADULT; AGED; BACTERIUM ISOLATE; CHILD; CONFERENCE PAPER; CRITICAL ILLNESS; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INFANT; LUNG INFECTION; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SEASONAL VARIATION; STENOTROPHOMONAS MALTOPHILIA;

EID: 0035873153     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/320183     Document Type: Conference Paper

References (53)

1. Acinetobacter species as nosocomial pathogens: Microbiological, clinical, and epidemiological features
2. National Nosocomial Infection Surveillance (NNIS) system report: Data summary from October 1986-April 1998, issued June 1998
3. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study
4. Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6)
5. Antimicrobial susceptibility of Acinetobacter species
6. The distribution of Acinetobacter species in clinical culture materials
7. Molecular heterogeneity of Acinetobacter baumannii isolates during seasonal increase in prevalence
8. Seasonal variation of acinetobacter infections, 1987-1996
9. Community-acquired acinetobacter pneumonia in the Northern Territory of Australia
10. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam
11. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods
12. Worldwide emergence of carbapenem-resistant Acinetobacter species
13. Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain
14. Prevalence of Acinetobacter species isolates with reduced susceptibility to imipenem, as determined by a USA-wide electronic surveillance network
15. Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia
16. Risk assessment of opportunistic bacterial pathogens in drinking water
17. Two consecutive outbreaks of Stenotrophomonas maltophilia (Xanthomonas maltophilia) in an intensive-care unit defined by restriction fragment-length polymorphism typing
18. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia
19. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies
20. Nosocomial infection caused by Xanthomonas maltophilia: A case-control study of predisposing factors
21. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer
22. Xanthomonas maltophilia and Pseudomonas cepacia in lower respiratory tracts of patients in critical care units
23. Stenotrophomonas maltophilia bacteraemia in cancer patients: Report on 31 cases
24. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: A prospective, multicenter study of 91 episodes
25. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: Role of severe neutropenia and mucositis
26. Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature
27. Infective endocarditis due to Stenotrophomonas (Xanthomonas) maltophilia
28. Stenotrophomonas maltophilia in cystic fibrosis patients
29. Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patients
30. Correlation between genotype and beta-lactamases of clinical and environmental strains of Stenotrophomonas mahophilia
31. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen
32. Stenotrophomonas maltophilia infection and colonization in the intensive care units of two community hospitals. A study of 143 patients
33. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens
34. Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873
35. Sensitivity of L-2 type beta-lactamases from Stenotrophomonas maltophilia to serine active site beta-lactamase inhibitors
36. Overexpression, purification, and characterization of the cloned metallo-beta-lactamase L1 from Stenotrophomonas maltophilia
37. Multiple antibiotic resistance in Stenotrophomonas maltophilia: Involvement of a multidrug efflux system
38. Antibiotic susceptibility of Stenotrophomonas (Xanthomonas) maltophilia: Comparative (NCCLS criteria) evaluation of antimicrobial drugs with the agar dilution and the agar disk diffusion (Bauer-Kirby) tests
39. In vitro susceptibility of Pseudomonas cepacia and Pseudomonas maltophilia to trimethoprim and trimethoprim-sulfamethoxazole
40. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: Implications for therapy
41. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem
42. Survey of blood stream infections due to gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997
43. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: Clinical features, molecular epidemiology, and antimicrobial susceptibility
44. Use of macrorestriction analysis to demonstrate interhospital spread of multiresistant Acinetobacter baumannii in São Paulo, Brazil
45. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gramnegative bacilli: Occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes
46. Activities of beta-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods
47. Six-year prospective study of risk and prognostic factors in patients with nosocomial sepsis caused by Acinetobacter baumannii
48. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer
49. Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods
50. Comparative activity, of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia
51. Antimicrobial resistance in developing countries
52. United States geographic bacteria susceptibility patterns